Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East Tech Today.
Press releases published on May 8, 2025

Rumble Reports First Quarter 2025 Results
~ Revenue up 34% Year-over-Year to $23.7 Million ~ ~ Rumble Cloud Secures Contract with Government of El Salvador ~ ~ Significantly Improved MAU Retention Compared to 2022 Mid-Term Elections ~ ~ Tether Investment Completed, Balance Sheet Solidified ~ …

AvePoint Announces First Quarter 2025 Financial Results
First quarter SaaS revenue of $68.9 million, representing 34% year-over-year growth, 37% on a constant currency basis First quarter Total revenue of $93.1 million, representing 25% year-over-year growth, 27% on a constant currency basis Total ARR of $345.5 …

Fulcrum Therapeutics to Participate in Upcoming May Conferences
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare …

Cytek Biosciences Reports First Quarter 2025 Financial Results
FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025. First …

Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates
Presented positive 4- and 12-week clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to function and persist with …

IBEX Reports Record Quarterly Revenue and EPS, Returns to Double-Digit Growth, Raises Fiscal Year Guidance
Quarterly revenue grew 11% versus prior year quarter - highest growth in ten quarters Adjusted EPS of $0.82 - an increase of 18% to prior year quarter Makes strategic entry into India - launching with leading healthcare client Board authorizes a new $15 …

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 in 2L+ CML Additional safety and efficacy data including 6-month MMR expected in 4Q25 Phase 2 FALCON trial of TERN-601 for obesity is enrolling well with top-line 12-week weight loss data …

Lantronix Reports Results for Third Quarter of Fiscal 2025
Third Quarter Net Revenue of $28.5 Million Third Quarter GAAP EPS of ($0.10) Third Quarter Non-GAAP EPS of $0.03 IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity for the Internet of …

TELA Bio Reports First Quarter 2025 Financial Results
MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended …

CEA Industries Inc. Provides Update on Fat Panda Acquisition
Transaction reflects CEA Industries’ strategic evolution and pivotal entry into attractive high-growth vape market Accelerates Fat Panda’s growth initiatives as central Canada’s largest retailer and manufacturer of e-cigarettes, vape devices and e-liquids …

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update
- Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Expanded intellectual property portfolio with second patent covering …

Synaptics Reports Third Quarter Fiscal 2025 Results
Quarterly revenues increased 12% year-over-year, driven by a 43% growth in Core IoT product sales Q3’25 Financial Results Revenue of $266.6 million GAAP gross margin of 43.4% Non-GAAP gross margin of 53.5% GAAP loss per share of $0.56 Non-GAAP diluted …

Snail, Inc. Sets First Quarter 2025 Conference Call for Wednesday, May 14, 2025 at 4:30 p.m. ET
CULVER CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, will hold a conference call and webcast on …

Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2025
FRAMINGHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended March …

SIGA Reports Financial Results for Three Months Ended March 31, 2025
Received $26 Million IV TPOXX Procurement Order from the U.S. Government in March $94 million in TPOXX Orders (to be Delivered to U.S. Strategic National Stockpile) outstanding as of March 31, 2025 Corporate Update Conference Call Today at 4:30 PM ET NEW …

Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025
REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will present data from its …

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Activities supporting the close out of BEACON-IPF continue; topline data expected in the second quarter of 2025 Recently announced strategic realignment of workforce and operations will extend cash runway to support execution of late-stage clinical trials …

NurExone Advances Vision Restoration Strategy with Preclinical Data Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025
TORONTO and HAIFA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system …

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results
Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3 registrational clinical trial of …

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025
1Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained 2025 Regulatory Approvals for Amtagvi® Expected in the UK, EU, and Canada On Track to …